Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors Meeting Abstract
| Authors: | Segal, N. H.; Infante, J. R.; Sanborn, R. E.; Gibney, G. T.; Lawrence, D. P.; Rizvi, N.; Leidner, R.; Gajewski, T. F.; Bertino, E.; Sharfman, W. H.; Cooley, S.; Topalian, S. L.; Urba, W. J.; Wolchok, J. D.; Gu, X.; Passey, C.; McDonald, D.; Aanur, P.; Srivastava, S.; Hodi, F. S. |
| Abstract Title: | Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi372 |
| Language: | English |
| ACCESSION: | WOS:000393913000180 |
| DOI: | 10.1093/annonc/mdw378.40 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- 1086P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
